RA Capital Nexus Fund II, L.P.
CIK 1825376 · last filed 2025-06-13
RA Capital Nexus Fund II, L.P. is a corporate insider who has filed 14 SEC Form 4 insider transactions across 10 companies since 2022. The most recent filing, for JANX, was dated Jun 13, 2025. Across all open-market trades the lifetime net is +$697.3M, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $127.2M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$127.21M
10
14
$697.31M
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| JANX | Director | 1,048,406 | $13.56 | $14.22M | $0 | 4 | 2025-06-13 |
| LENZ | Director | — | $6.77 | — | $0 | 1 | 2025-06-11 |
| PEPG | Director | — | $1.47 | — | $0 | 1 | 2025-06-06 |
| Climb Bio, Inc. (ELYM) Delisted | Director | 841,087 | $5.11 | $4.30M | $349.67M | 1 | 2024-07-01 |
| HOWL | Director | — | $0.38 | — | $0 | 1 | 2024-05-24 |
| ACRV | Director | 7,914,206 | $1.48 | $11.71M | $0 | 1 | 2024-04-15 |
| Icosavax, Inc. (ICVX) Delisted | Director | 0 | $15.31 | $0 | $4.18M | 2 | 2024-02-20 |
| SPRY | Director | 8,556,774 | $9.76 | $83.51M | $40.92M | 1 | 2023-09-25 |
| DICE Therapeutics, Inc. (DICE) Delisted | Director | 6,848,911 | $47.55 | $325.67M | $299.30M | 1 | 2022-10-19 |
| ANTX | 10%+ Owner | 3,748,087 | $4.74 | $17.77M | $3.24M | 1 | 2022-06-15 |
Recent Filings
14 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2025-06-13 | JANX | Grant (A) | +18,750 | $0 | EDGAR |
| 2025-06-11 | LENZ | Grant (A) | — | $0 | EDGAR |
| 2025-06-06 | PEPG | Grant (A) | — | $0 | EDGAR |
| 2024-07-01 | Climb Bio, Inc. (ELYM) Delisted | Mixed | +127,878,926 | $349.67M | EDGAR |
| 2024-06-28 | JANX | Grant (A) | +12,500 | $0 | EDGAR |
| 2024-05-24 | HOWL | Grant (A) | — | $0 | EDGAR |
| 2024-04-15 | ACRV | Grant (A) | +17,650,000 | $150.03M | EDGAR |
| 2024-03-06 | JANX | Buy (P) | — | $0 | EDGAR |
| 2024-02-20 | Icosavax, Inc. (ICVX) Delisted | Mixed | −29,845,540 | $0 | EDGAR |
| 2023-09-25 | SPRY | Buy (P) | +13,500,000 | $40.92M | EDGAR |